{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:16Z","timestamp":1786982836708,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the italian ministry of university and research","award":["PRIN 2017-HBHA98"],"award-info":[{"award-number":["PRIN 2017-HBHA98"]}]},{"DOI":"10.13039\/100008373","name":"takeda pharmaceutical company","doi-asserted-by":"publisher","award":["Investigator-initiated research ID IIR-ITA-001335"],"award-info":[{"award-number":["Investigator-initiated research ID IIR-ITA-001335"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40618-021-01686-2","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T18:11:29Z","timestamp":1634062289000},"page":"573-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Renal complications and quality of life in postsurgical hypoparathyroidism: a case\u2013control study"],"prefix":"10.1007","volume":"45","author":[{"given":"L.","family":"Mazoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Apicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Saponaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Borsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cosci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pacciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scionti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-9547","authenticated-orcid":false,"given":"F.","family":"Cetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"1686_CR1","unstructured":"Food and Drugs Administration NATPARA:shire-NPS Pharmaceuticals, Inc, 2015. www.fda.gov\/medwatch. Accessed 13 Apr 2021"},{"key":"1686_CR2","unstructured":"European Medicine Agency (2017) First hormone replacement therapy for hypoparathyroidism"},{"key":"1686_CR3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","volume":"173","author":"J Bollerslev","year":"2015","unstructured":"Bollerslev J, Rejnmark L, Marcocci C et al (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. J Clin Endocrinol Metab 173:G1\u2013G20. https:\/\/doi.org\/10.1530\/EJE-15-0628","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR4","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1210\/jc.2015-3907","volume":"101","author":"ML Brandi","year":"2016","unstructured":"Brandi ML, Bilezikian JP, Shoback D et al (2016) Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab 101:2273\u20132283. https:\/\/doi.org\/10.1210\/jc.2015-3907","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1210\/jc.2015-3910","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Brandi ML, Cusano NE et al (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313\u20132324. https:\/\/doi.org\/10.1210\/jc.2015-3910","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR6","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1210\/jc.2012-1808","volume":"97","author":"DM Mitchell","year":"2012","unstructured":"Mitchell DM, Regan S, Cooley MR et al (2012) Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab 97:4507\u20134514. https:\/\/doi.org\/10.1210\/jc.2012-1808","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jbmr.1979","volume":"28","author":"L Underbjerg","year":"2013","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277\u20132285. https:\/\/doi.org\/10.1002\/jbmr.1979","journal-title":"J Bone Miner Res"},{"key":"1686_CR8","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/jbmr.2273","volume":"29","author":"L Underbjerg","year":"2014","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014) Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res 29:2504\u20132510. https:\/\/doi.org\/10.1002\/jbmr.2273","journal-title":"J Bone Miner Res"},{"key":"1686_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jbmr.3368","volume":"33","author":"L Underbjerg","year":"2018","unstructured":"Underbjerg L, Sikjaer T, Rejnmark L (2018) Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study. J Bone Miner Res 33:822\u2013831. https:\/\/doi.org\/10.1002\/jbmr.3368","journal-title":"J Bone Miner Res"},{"key":"1686_CR10","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/S12325-021-01658-1","volume":"38","author":"EO Gosmanova","year":"2021","unstructured":"Gosmanova EO, Chen K, Rejnmark L et al (2021) Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 38:1876. https:\/\/doi.org\/10.1007\/S12325-021-01658-1","journal-title":"Adv Ther"},{"key":"1686_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14470","author":"LO Ridder","year":"2021","unstructured":"Ridder LO, Harsl\u00f8f T, Sikj\u00e6r T et al (2021) Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: a cross-sectional study. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.14470","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1686_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40618-018-0857-5","volume":"41","author":"A Meola","year":"2018","unstructured":"Meola A, Vignali E, Matrone A et al (2018) Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 41:1221\u20131226. https:\/\/doi.org\/10.1007\/s40618-018-0857-5","journal-title":"J Endocrinol Invest"},{"issue":"44","key":"1686_CR13","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/S40618-020-01442-Y","volume":"447","author":"NAT Hamdy","year":"2020","unstructured":"Hamdy NAT, Decallonne B, Evenepoel P et al (2020) Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey. J Endocrinol Investig 447(44):1437\u20131446. https:\/\/doi.org\/10.1007\/S40618-020-01442-Y","journal-title":"J Endocrinol Investig"},{"key":"1686_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4158\/EP13328.OR","volume":"20","author":"N Hadker","year":"2014","unstructured":"Hadker N, Egan J, Sanders J et al (2014) Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract 20:671\u2013679. https:\/\/doi.org\/10.4158\/EP13328.OR","journal-title":"Endocr Pract"},{"key":"1686_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa597","author":"M B\u00fcttner","year":"2020","unstructured":"B\u00fcttner M, Locati LD, Pinto M et al (2020) Quality of life in patients with hypoparathyroidism after treatment for thyroid cancer. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa597","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J et al (2020) Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13-country patient and caregiver survey. Clin Endocrinol (Oxf) 92:159\u2013168. https:\/\/doi.org\/10.1111\/cen.14128","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1686_CR17","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1210\/jc.2016-1477","volume":"101","author":"MC Astor","year":"2016","unstructured":"Astor MC, L\u00f8vas K, Debowska A et al (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045\u20133053. https:\/\/doi.org\/10.1210\/jc.2016-1477","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A et al (2014) Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int 25:1717\u20131726. https:\/\/doi.org\/10.1007\/s00198-014-2677-6","journal-title":"Osteoporos Int"},{"key":"1686_CR19","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1210\/jc.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"Cusano NE, Rubin MR, McMahon DJ et al (2014) PTH(1\u201384) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab 99:3694\u20133699. https:\/\/doi.org\/10.1210\/jc.2014-2267","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F et al (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215\u2013222. https:\/\/doi.org\/10.1530\/eje.0.1460215","journal-title":"Eur J Endocrinol"},{"key":"1686_CR21","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/jbmr.2812","volume":"31","author":"T Sikjaer","year":"2016","unstructured":"Sikjaer T, Moser E, Rolighed L et al (2016) Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism. J Bone Miner Res 31:1440\u20131448. https:\/\/doi.org\/10.1002\/jbmr.2812","journal-title":"J Bone Miner Res"},{"key":"1686_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/OXFORDJOURNALS.AJE.A114716","volume":"126","author":"SR Cummings","year":"1987","unstructured":"Cummings SR, Block G, McHenry K, Baron RB (1987) Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 126:796\u2013802. https:\/\/doi.org\/10.1093\/OXFORDJOURNALS.AJE.A114716","journal-title":"Am J Epidemiol"},{"key":"1686_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"key":"1686_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40618-019-01162-y","volume":"43","author":"F Saponaro","year":"2020","unstructured":"Saponaro F, Cetani F, Mazoni L et al (2020) Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism? J Endocrinol Invest 43:677\u2013682. https:\/\/doi.org\/10.1007\/s40618-019-01162-y","journal-title":"J Endocrinol Invest"},{"key":"1686_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","volume":"84","author":"CW Topp","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P (2015) The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom 84:167\u2013176. https:\/\/doi.org\/10.1159\/000376585","journal-title":"Psychother Psychosom"},{"key":"1686_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02629-w","author":"AA Khan","year":"2021","unstructured":"Khan AA, AbuAlrob H, Punthakee Z et al (2021) Canadian national hypoparathyroidism registry: an overview of hypoparathyroidism in Canada. Endocrine. https:\/\/doi.org\/10.1007\/s12020-021-02629-w","journal-title":"Endocrine"},{"issue":"43","key":"1686_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/S40618-019-01173-9","volume":"436","author":"T Akkan","year":"2020","unstructured":"Akkan T, Dagdeviren M, Koca AO et al (2020) Alternate-day calcium dosing may be an effective treatment option for chronic hypoparathyroidism. J Endocrinol Investig 436(43):853\u2013858. https:\/\/doi.org\/10.1007\/S40618-019-01173-9","journal-title":"J Endocrinol Investig"},{"key":"1686_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa490","volume":"105","author":"KS Chen","year":"2020","unstructured":"Chen KS, Gosmanova EO, Curhan GC et al (2020) Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1\u201384). J Clin Endocrinol Metab 105:1\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgaa490","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0272-6386(03)00905-3","volume":"42","author":"G Eknoyan","year":"2003","unstructured":"Eknoyan G, Levin A, Levin NW (2003) Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1\u2013201. https:\/\/doi.org\/10.1016\/s0272-6386(03)00905-3","journal-title":"Am J Kidney Dis"},{"key":"1686_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/EJE-18-0580","volume":"180","author":"K David","year":"2019","unstructured":"David K, Moyson C, Vanderschueren D, Decallonne B (2019) Long-term complications in patients with chronic Hypoparathyroidism: a cross-sectional study. Eur J Endocrinol 180:71\u201378. https:\/\/doi.org\/10.1530\/EJE-18-0580","journal-title":"Eur J Endocrinol"},{"key":"1686_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1590\/2359-3997000000221","volume":"60","author":"MP Lopes","year":"2016","unstructured":"Lopes MP, Kliemann BS, Bini IB et al (2016) Hypoparathyroidism and pseudohypoparathyroidism: etiology, laboratory features and complications. Arch Endocrinol Metab 60:532\u2013536. https:\/\/doi.org\/10.1590\/2359-3997000000221","journal-title":"Arch Endocrinol Metab"},{"key":"1686_CR32","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1007\/s12325-021-01649-2","volume":"38","author":"M Ketteler","year":"2021","unstructured":"Ketteler M, Chen K, Gosmanova EO et al (2021) Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther 38:1946\u20131957. https:\/\/doi.org\/10.1007\/s12325-021-01649-2","journal-title":"Adv Ther"},{"key":"1686_CR33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa233","author":"F Saponaro","year":"2020","unstructured":"Saponaro F, Marcocci C, Apicella M et al (2020) Hypomagnesuria is associated with nephrolithiasis in patients with asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa233","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR34","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ et al (2013) The effect of PTH(1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98:2356\u20132361. https:\/\/doi.org\/10.1210\/jc.2013-1239","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neuroscience.2009.04.054","volume":"162","author":"AG Bag\u00f3","year":"2009","unstructured":"Bag\u00f3 AG, Dimitrov E, Saunders R et al (2009) Parathyroid hormone 2 receptor and its endogenous ligand tuberoinfundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience 162:128\u2013147. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.04.054","journal-title":"Neuroscience"},{"key":"1686_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.physbeh.2017.09.005","volume":"181","author":"B Gell\u00e9n","year":"2017","unstructured":"Gell\u00e9n B, Zelena D, Usdin TB, Dobolyi \u00c1 (2017) The parathyroid hormone 2 receptor participates in physiological and behavioral alterations of mother mice. Physiol Behav 181:51\u201358. https:\/\/doi.org\/10.1016\/j.physbeh.2017.09.005","journal-title":"Physiol Behav"},{"key":"1686_CR37","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1210\/JC.2017-02593","volume":"103","author":"KK Winer","year":"2018","unstructured":"Winer KK (2018) Does PTH replacement therapy improve quality of life in patients with chronic hypoparathyroidism? J Clin Endocrinol Metab 103:2752. https:\/\/doi.org\/10.1210\/JC.2017-02593","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR38","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1210\/jc.2002-021736","volume":"88","author":"KK Winer","year":"2003","unstructured":"Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214\u20134220. https:\/\/doi.org\/10.1210\/jc.2002-021736","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1210\/jc.2017-01471","volume":"103","author":"TJ Vokes","year":"2018","unstructured":"Vokes TJ, Mannstadt M, Levine MA et al (2018) Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab 103:722\u2013731. https:\/\/doi.org\/10.1210\/jc.2017-01471","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR40","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/jc.2018-02430","volume":"104","author":"G Tabacco","year":"2019","unstructured":"Tabacco G, Tay YKD, Cusano NE et al (2019) Quality of life in hypoparathyroidism improves with rhPTH(1\u201384) throughout 8 years of therapy. J Clin Endocrinol Metab 104:2748\u20132756. https:\/\/doi.org\/10.1210\/jc.2018-02430","journal-title":"J Clin Endocrinol Metab"},{"key":"1686_CR41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bcp.13455","volume":"84","author":"D Tay","year":"2018","unstructured":"Tay D, Cremers S, Bilezikian JP (2018) Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism\u2014translating the pharmacology. Br J Clin Pharmacol 84:252\u2013267","journal-title":"Br J Clin Pharmacol"},{"key":"1686_CR42","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAB577","author":"AA Khan","year":"2021","unstructured":"Khan AA, Rejnmark L, Rubin M et al (2021) PaTH Forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB577","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T10:34:31Z","timestamp":1645007671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1686"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01686-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Filomena Cetani is a member the Editorial Board of this Journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the Local Ethic Committee (CEAVNO-Comitato Etico Area Vasta Nord Ovest). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}